Ireland's Uniphar 2025 revenue up 11%, beats estimates on strong demand in Global Sourcing

Uniphar

24/02/2026 07:11

Overview

Irish healthcare services firm's 2025 revenue grew 11%, beating analyst expectations

Adjusted EPS for 2025 rose 21%, beating analyst expectations

Company completed €35 mln share buyback program

Outlook

Uniphar expects continued organic Gross Profit growth in line with medium-term targets

Company aims for €200m EBITDA by 2028, with 80% organic growth

Uniphar sees strong trading momentum entering 2026

Result Drivers

PHARMA GROWTH - Uniphar Pharma achieved 15.5% organic Gross Profit growth, driven by strong demand in Global Sourcing and clinical trial supply

MEDTECH EXPANSION - Uniphar Medtech reported 10.5% organic Gross Profit growth, supported by geographic expansion and new supplier rollouts

SUPPLY CHAIN VOLUME - Uniphar Supply Chain & Retail saw 4.2% organic Gross Profit growth, with strong volume growth in Supply Chain

Company press release: ID:nRSX0830Ua

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
EUR 3.07 bln
EUR 2.97 bln (8 Analysts)
FY Adjusted EPS
Beat
EUR 0.25
EUR 0.24 (8 Analysts)
FY Adjusted Pretax Profit
EUR 71.80 mln
FY Basic EPS
EUR 0.20
FY Gross Profit
EUR 457.69 mln
FY Operating Income
EUR 76.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Uniphar PLC is €4.84, about 21.2% above its February 23 closing price of €4.00

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)